文献速递关节外科

丙型肝炎术前治疗与美国退伍军人人工关节感染率降低相关

Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans.
PubMed 文献 · J Arthroplasty · 2019-03-09

该回顾性研究基于美国退伍军人事务部2014至2018年连续初次全关节置换术数据集,比较术前接受直接抗病毒药物(DAA)治疗的HCV感染患者与未治疗者的术后并发症;结果显示治疗组在术后90天和1年的假体周围感染率在统计学上低于未治疗组,作者认为术前HCV治疗与较低的假体周围感染率相关,但需进一步研究才能得出明确结论。

要点

  • 在42,268例全关节置换术患者中,约6.0%(n=2557)合并HCV感染,其中17.3%术前接受了HCV治疗。
  • HCV治疗组术后90天和1年的假体周围感染率在统计学上低于未治疗组(90天OR 3.30,P=.045;1年OR 2.16,P=.07)。
  • 作者认为术前HCV治疗与美国退伍军人全关节置换术后较低的假体周围感染率相关,但需进一步研究才能得出明确结论。

核心结论

  • 术前HCV治疗与美国退伍军人全关节置换术后较低的假体周围感染率相关,但需进一步研究才能得出明确结论。

研究设计与样本

  • 回顾性审查美国退伍军人事务部2014至2018年DAA可用期间所有连续初次全关节置换术数据集。
  • 通过国际疾病分类第九版和第十版编码及实验室值识别HCV感染患者,术前接受DAA治疗者归入治疗组,术前未治疗者归入未治疗组。
  • 通过国际疾病分类第九版和第十版住院和门诊编码识别术后至1年的内科和外科并发症。

主要发现

  • 2014至2018年间共有42,268例患者在美国退伍军人事务部医院接受全关节置换术,约6.0%(n=2557)合并HCV感染,其中17.3%术前接受了HCV治疗。
  • 在评估住院和门诊编码时,HCV治疗组术后90天和1年的假体感染率在统计学上低于未治疗组。
  • 比值比(OR)支持HCV治疗组感染率较低(90天OR 3.30,P=.045;1年OR 2.16,P=.07)。

局限性

  • 作者指出需进一步研究才能得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) is associated with poorer outcomes in total joint arthroplasty (TJA). Recently, oral direct-acting antivirals (DAAs) have become available for HCV curative treatment. The goal of this study is to determine if HCV may be a modifiable risk factor in TJA by comparing postoperative complications among patients with and without preoperative treatment for HCV. METHODS: US Department of Veterans Affairs dataset of all consecutive primary TJAs performed between 2014 and 2018, when DAAs were available, was retrospectively reviewed. HCV-infected patients were identified using International Classification of Diseases, Ninth and Tenth Revision codes and laboratory values. HCV-infected patients treated prior to TJA with DAA were included in the "treated" group. HCV-infected patients untreated preoperatively were assigned to the "untreated" group. Medical and surgical complications up to 1 year postoperatively were identified using International Classification of Diseases, Ninth and Tenth Revision inpatient and outpatient codes. RESULTS: In total, 42,268 patients underwent TJA at Veterans Affairs Hospitals between 2014 and 2018. About 6.0% (n = 2557) of TJA patients had HCV, 17.3% of whom received HCV treatment preoperatively. When evaluating inpatient and outpatient codes, implant infection rates were statistically lower at 90 days and 1 year postoperatively among HCV-treated patients than among those untreated. Odds ratios (ORs) favor lower infection rates in HCV-treated patients (90-day OR: 3.30, P = .045; 1-year OR: 2.16, P = .07). CONCLUSION: Preoperative HCV treatment was associated with lower periprosthetic infection rates among US veterans undergoing TJA. Further investigation is necessary for definitive conclusions.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Bendich I, Takemoto S, Patterson JT, et al. Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans. J Arthroplasty. 2019. PMID: 30930157. doi:10.1016/j.arth.2019.02.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。